Short answer
Sanara MedTech Inc. (SMTI) filed an 8-K current report with the SEC on July 29, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Sanara to be acquired by MiMedx in a cash-and-stock merger: $33.00 cash plus 0.4735 MiMedx shares per SMTI share.
Sanara MedTech Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Sanara to be acquired by MiMedx in a cash-and-stock merger: $33.00 cash plus 0.4735 MiMedx shares per SMTI share
- Implied stock component valued at $2.00 per share, bringing stated merger consideration to $35.00 per share
- Stockholder approval requires majority support; voting agreements cover approximately 38.9% of voting power
- Closing remains subject to antitrust clearances, effective Form S-4 registration, Nasdaq listing, and customary conditions
- Termination fees: $22,540,785 payable by Sanara in specified scenarios and $9,660,336 payable by MiMedx for failure to close
Item 7.01 · Regulation FD Disclosure
- Proposed Sanara–MiMedx business combination remains subject to regulatory approvals and Sanara stockholder approval
- MiMedx intends to file Form S-4 incorporating Sanara’s proxy statement and MiMedx’s prospectus
- Closing timing remains uncertain, with potential termination fee exposure for Sanara
- Key risks include litigation, transaction costs, operational disruption, personnel retention and adverse stock-price effects
- Investors should await the definitive proxy statement/prospectus before voting or making investment decisions
Item EX-99.1 · Exhibit EX-99.1
- MIMEDX agreement to acquire Sanara for $35 per share, valuing the transaction at approximately $350 million enterprise value
- Sanara shareholders receive $33 cash plus 0.4735 MIMEDX shares, representing a 46% premium to Sanara’s 30-day VWAP
- MIMEDX expects nearly doubled surgical revenue and over $20 million in run-rate cost synergies
- Combined 2027 revenue expected well above $400 million with adjusted EBITDA margin over 20%
- $300 million Hayfin term loan plus cash-on-hand financing increases leverage; closing targeted by year-end pending shareholder and regulatory approvals
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Sanara MedTech Inc. 8-K filings
Get the next SMTI 8-K as it lands
Follow SMTI for push alerts, or ask the research agent what this filing means.